Would have thought that estimating PTRS for emerging biotechs with little clinical history and developing a new modality , perhaps in a rare disease would be challenging. Surely many areas of uncertainty?
It's certainly challenging to come up with accurate PTRS metrics for early stage clinical or preclinical drug programs. The closer you are to approval, the more accurate your PTRS. For rare diseases, where many don't even have approved drugs to benchmark against, it's even more difficult.
Would have thought that estimating PTRS for emerging biotechs with little clinical history and developing a new modality , perhaps in a rare disease would be challenging. Surely many areas of uncertainty?
It's certainly challenging to come up with accurate PTRS metrics for early stage clinical or preclinical drug programs. The closer you are to approval, the more accurate your PTRS. For rare diseases, where many don't even have approved drugs to benchmark against, it's even more difficult.